A Study of SAR428926 in Patients With Advanced Solid Tumors

Inclusion criteria : * Patients with advanced solid tumor with no standard alternative treatment. * Availability of archived tumor tissue for SAR428926 targeted antigen testing. * For participants in the Escalation Phase: human epidermal growth factor receptor 2 (HER2) negative breast cancer (BC), gastric cancer, colorectal cancer (CRC), ovarian cancer, prostate cancer and non small-cell lung cancer (NSCLC). * For participants in the Expansion Phase: patients with TNBC, prostate cancer, CRC, ovarian cancer or NSCLC and positive SAR428926 targeted antigen. * At least one measurable lesion according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 and one lesion amenable to biopsy in expansion cohort only (except for NSCLC patients). Exclusion criteria: * Age less than 18 years old. * Eastern Cooperative Oncology Group (ECOG) performance status more than 1. * New or progressing brain metastases. * Concurrent treatment with any other anticancer therapy or inadequate wash-out period for prior anticancer therapies, including other experimental anticancer treatment, before first administration of SAR428926, or non resolution of toxicities induced by these anticancer therapies. * Women of reproductive potential and male subjects with female partners of childbearing potential who are not willing to avoid pregnancy. * Pregnancy or breast feeding. * Prior maytansinoid treatments (DM1 or DM4 antibody drug conjugates \[ADCs\]). * Unwillingness and inability to comply with scheduled visits, drug administration plan, laboratory tests, other study procedures, and study restrictions. * Significant concomitant illness, including psychiatric condition that, in the opinion of the Investigator or Sponsor, would adversely affect the patient's participation in the study. * Any surgery within the preceding 3 weeks. * Known human immunodeficiency virus (HIV) infection or active hepatitis B or C viral infection. * Poor bone marrow reserve. * Poor kidney and liver function. * Previous history of chronic corneal diseases (even if asymptomatic) or unresolved acute non-recurrent corneal conditions. Patients wearing contact lenses who are not willing to stop wearing them for the duration of the study. * Unresolved signs and symptoms of peripheral neuropathy; Grade 1 is acceptable. * Abnormal cardiac function defined by a left ventricular ejection fraction (LVEF) \<50%. * Known intolerance to infused protein products including other monoclonal antibodies and ADCs. * Medical conditions requiring concomitant administration of medications with narrow therapeutic window, metabolized by CYPs and which a dose reduction cannot be considered. * Medical conditions requiring concomitant administration of strong CYP3A inhibitors, unless it can be discontinued at least two weeks before first administration of SAR428926. * Other prior neoplasm. * Contraindications to the use of ophthalmic vasoconstrictor and/or corticosteroid as per package insert of each drug, including the following: increase intraocular pressure, prior or current glaucoma, narrow-angle glaucoma, ongoing eye infection, uncontrolled hypertension, known/suspected allergy to constituents of the preparation (such as sodium bisulfite). The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.